Core Insights - 甘李药业 has entered into an exclusive licensing and commercialization agreement with Productos Científicos S.A. de C.V. to develop and commercialize its GLP-1RA drug, GZR18, in Latin America, marking its first international output of self-developed innovative drugs [1] - The collaboration combines 甘李药业's innovative research capabilities with the local advantages of PC to tap into the rapidly growing market for diabetes and obesity treatments in Latin America [2] Market Potential - The GLP-1 receptor agonist market in Latin America is projected to reach USD 1.323 billion in 2024, with expectations to exceed USD 3.5 billion by 2030, reflecting a compound annual growth rate (CAGR) of 16.8% from 2025 to 2030 [2] - The demand for convenient medication and treatment adherence in the region is increasing, making the bi-weekly administration of GLP-1RA formulations advantageous due to lower dosing frequency and improved treatment experience [2] Product Development - GZR18 is an innovative bi-weekly GLP-1RA formulation developed by 甘李药业, focusing on the treatment of type 2 diabetes and weight management for overweight individuals, showing promising results in both glycemic control and weight loss [3] - The company is accelerating the global clinical development of GZR18, with plans for Phase III clinical trials for weight loss and head-to-head trials against competitors scheduled for 2024 and 2025 [3] International Strategy - This licensing agreement represents a significant breakthrough for 甘李药业 in the Latin American market, following a previous long-term supply agreement worth no less than RMB 3 billion with a Brazilian pharmaceutical company [4] - The dual strategy of targeting both "mature products" and "innovative pipelines" illustrates the company's approach to solidifying its revenue base while unlocking long-term valuation through innovative drug licensing [4] - Analysts note that 甘李药业 is experiencing dual momentum from domestic recovery and international acceleration, with projected sales growth of 55.28% domestically and 74.68% internationally in the first half of 2025 [4]

Core Viewpoint - Gannee Pharmaceutical has entered into an exclusive licensing and commercialization agreement with Productos Científicos S.A. de C.V. to develop and commercialize its GLP-1 receptor agonist GZR18 in Latin America, marking the company's first international output of self-developed innovative drugs [1] Group 1: Market Potential and Product Advantages - The Latin American GLP-1 receptor agonist market is projected to reach $1.3232 billion in 2024, with expectations to exceed $3.5 billion by 2030, reflecting a compound annual growth rate (CAGR) of 16.8% from 2025 to 2030 [2] - The bi-weekly administration of GZR18 offers significant advantages in terms of convenience and treatment adherence, making it a favorable option in a region with high diabetes and obesity rates [2] Group 2: Clinical Development and Efficacy - GZR18 has shown promising results in clinical trials for both glycemic control and weight loss, potentially becoming the first bi-weekly GLP-1RA to market globally [3] - The company is accelerating the global clinical development of GZR18, with plans for head-to-head trials against Novo Nordisk products starting in 2025 [3] Group 3: International Strategy and Market Growth - The agreement with PC represents Gannee Pharmaceutical's second major breakthrough in the Latin American market, following a long-term supply agreement worth no less than 3 billion RMB with a Brazilian company [4] - The dual strategy of leveraging both mature products and innovative pipelines positions the company for sustained revenue growth and long-term valuation enhancement [4] Group 4: Financial Performance and R&D Investment - Gannee Pharmaceutical is experiencing a dual boost from domestic recovery and international acceleration, with projected sales growth of 55.28% domestically and 74.68% internationally in the first half of 2025 [5] - The company has invested 883 million RMB in R&D in the first three quarters of 2025, supporting the global clinical development of core products like GZR18 [5]

Core Insights - 甘李药业 has been recognized as a manufacturing single champion enterprise, marking its status as a leading company in the biopharmaceutical sector with its core product, "Insulin Glargine Injection" [1][2] - The recognition reflects 甘李药业's advanced production technology and significant market share in the insulin analogs field, breaking the long-standing foreign monopoly in the domestic insulin market [1][2] Group 1: Company Achievements - 甘李药业 has established a self-controlled production system and a complete product line, including long-acting, rapid-acting, and premixed insulin [2] - The company has successfully passed the European Medicines Agency (EMA) GMP inspection, laying a solid foundation for entering the global regulated market [2] - In the first three quarters of 2025, domestic formulation revenue reached 2.624 billion yuan, a year-on-year increase of 45.6%, indicating a robust recovery in the domestic market [2] Group 2: Innovation and Future Prospects - Under the leadership of CEO Dr. Chen Wei, 甘李药业 is accelerating the development and global registration of innovative drugs, transitioning from "China's first imitation" to "global first creation" [3] - The company is expected to play a more significant role in the global value chain of the pharmaceutical industry, driven by steady growth in the domestic procurement market and accelerated expansion in the international high-end market [3]

Core Viewpoint - 甘李药业's stock has experienced fluctuations, with a year-to-date increase of 49.24% and a recent decline of 9.25% over the past 20 days, indicating volatility in its market performance [1][2]. Financial Performance - For the period from January to September 2025, 甘李药业 reported a revenue of 3.047 billion yuan, representing a year-on-year growth of 35.73%. The net profit attributable to shareholders was 818 million yuan, reflecting a significant increase of 61.32% compared to the previous year [2]. - The company has distributed a total of 1.612 billion yuan in dividends since its A-share listing, with 1.018 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for 甘李药业 increased to 94,700, marking a rise of 22.53%. The average number of circulating shares per shareholder decreased by 17.81% to 5,889 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 8.0042 million shares, an increase of 494,300 shares from the previous period [3].

Core Points - The first extraordinary general meeting of shareholders for 2025 was held on November 17, 2025, at the company's conference room in Tongzhou District, Beijing [2] - All resolutions proposed during the meeting were approved without any dissenting votes [2][4] - The meeting was legally convened and conducted in accordance with the Company Law of the People's Republic of China and the company's articles of association [2][7] Meeting Attendance - The meeting was chaired by the company's chairman, Mr. Chen Wei, with the attendance of all current directors and supervisors [2][3] - The company secretary and other senior executives were also present at the meeting [3] Resolutions Reviewed - The resolution to cancel the supervisory board and amend the articles of association was passed with more than two-thirds of the voting rights [4][6] - Several governance documents were revised and approved, including rules for shareholder meetings, board meetings, external guarantee systems, investment management methods, and related party transaction management [5][6] - A new remuneration management method for directors and senior management was established and approved [5][6] Legal Verification - The meeting was witnessed by lawyers from Zhonglun Law Firm, who confirmed that all procedures and resolutions complied with legal and regulatory requirements [7] Board Changes - Non-independent director Mr. Xu Fuming submitted his resignation due to adjustments in the company's governance structure, effective immediately upon receipt by the board [9][11] - Mr. Xu will continue to hold other positions within the company [9][11] - A new employee representative director was elected during the employee representative meeting held on November 17, 2025, following the approval of the supervisory board cancellation [12]

Group 1 - The company announced the election of Xu Fuming as the employee representative director of the fifth board of directors during the employee representative assembly held on November 17, 2025 [2]

Core Viewpoint - Gann Li Pharmaceutical (甘李药业) announced a governance structure adjustment, leading to the resignation of Xu Fuming from his position as a non-independent director of the fifth board of directors, while he will continue to hold other roles within the company [1] Group 1 - Xu Fuming applied to resign from his position as a non-independent director of the fifth board of directors [1] - Following his resignation, a workers' representative meeting was held to elect Xu Fuming as a workers' representative director of the fifth board of directors [1] - Xu Fuming's term as a workers' representative director will last until the end of the fifth board's term [1]

甘李药业股份有限公司 对外投资管理办法 第一章 总则 第一条 为规范甘李药业股份有限公司（以下简称"公司"）及公司的全资、 控股子公司的投资行为，降低投资风险，提高投资效益，依照《公司法》等国家 有关法律、法规及公司章程，制定本制度。 第二条 本制度所指投资仅指权益性投资。权益性投资包括各项股权投资、 债权投资、产权交易、公司重组以及合资合作等。 （四）与公司财务管理部门共同参与投资项目终（中）止清算与交接工作； （五）本制度规定的其他职能。 重大资本性支出如购置消费类资产（如车辆）、超过年度经营计划的技术改 造、基本建设、重大固定资产购置等不在本制度规范之内。 第三条 投资管理遵循的基本原则为：符合公司发展战略，合理配置企业资 源，促进要素优化组合，创造良好经济效益。 第二章 投资决策和管理机构 第四条 公司股东会、董事会依据公司章程确定的权限范围和程序对公司的 对外投资进行决策。 公司所有投资活动实行归口管理，公司投资管理部门由董事会确定。 第五条 公司投资管理部门的基本职能如下： （一）根据公司经营目标和发展规划编制并指导实施投资计划； （二）对投资项目的预选、策划、论证及实施进行管理与监督； （三）负 ...

第二条 本办法适用于公司董事、高级管理人员。 第三条 公司董事和高级管理人员薪酬将与公司经营业绩相结合，保障公司 稳定发展，但同时符合市场价值规律，公司薪酬制度遵循以下原则： （一）按岗位确定薪酬原则：公司内部各岗位薪酬体现各岗位对公司的价值； 甘李药业股份有限公司 董事、高级管理人员薪酬管理办法 第一章 总则 第一条 为进一步完善甘李药业股份有限公司（以下简称"公司"）董事、 高级管理人员的薪酬管理，建立和完善经营者的激励约束机制，保持核心管理团 队的稳定性，有效地调动董事、高级管理人员的工作积极性，提高公司经营管理 水平，促进公司健康、持续、稳定发展，根据《中华人民共和国公司法》《上市 公司治理准则》等有关法律、法规的规定及《甘李药业股份有限公司章程》（以 下简称《公司章程》），结合公司的实际情况，特制定本办法。 （二）按绩效评价标准、程序及主要评价体系的原则； （三）个人薪酬与公司长远利益相结合的原则； （四）激励与约束并重、奖罚对等的原则。 第二章 薪酬决策机构 第四条 公司董事会负责审议公司高级管理人员的薪酬；公司股东会负责审 议董事的薪酬。 第五条 公司董事会薪酬与考核委员会负责制定公司董事、高级 ...

甘李药业股份有限公司 董事会议事规则 第一章 总则 第一条 为明确甘李药业股份有限公司（以下简称"公司"）董事会的职责权 限，规范董事会的组织和行为，确保董事会的工作效率和科学决策，根据《中华 人民共和国公司法》（以下简称"公司法"）和《甘李药业股份有限公司章程》（以 下简称"公司章程"）的规定，制定本规则。 第二条 董事会是公司的常设机构，对股东会负责，执行股东会决议，维护 公司和全体股东的利益，负责公司发展目标和重大经营活动的决策。 第二章 董事 第三条 董事由自然人担任。有下列情形之一的，不能担任公司的董事： （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩序， 被判处刑罚，或者因犯罪被剥夺政治权利，执行期满未逾 5 年，被宣告缓刑的， 自缓刑考验期满之日起未逾 2 年； （三）担任破产清算的公司、企业的董事或者厂长、经理，对该公司、企业 的破产负有个人责任的，自该公司、企业破产清算完结之日起未逾 3 年； （四）担任因违法被吊销营业执照、责令关闭的公司、企业的法定代表人， 并负有个人责任的，自该公司、企业被吊销营业执照、责令关闭之日起未逾 3 ...